Nonprofit pharmaceutical to file for first drug approval in India; Flagship drug receives orphan drug designation from FDA, EMEA
WHAT Representatives from the Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., will be available at the BIO 2005 Annual International Convention to discuss how the biotechnology industry can partner in the company's innovative approaches to develop safe, effective and affordable new medicines for people with infectious disease in developing countries.
The company's first drug is on track for submission to the Indian regulatory authority by the end of this year. OneWorld Health's pipeline includes drugs for neglected infectious diseases, including visceral leishmaniasis (VL), Chagas disease, malaria and diarrhea. The company recently announced it received Orphan Drug Designation for paromomycin to treat visceral leishmaniasis (VL) from the two leading regulatory agencies in the world, the U.S. Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products.
More information is available at www.oneworldhealth.org
WHEN June 20-22
Mon. 9:30-5:00, Tues. 10:00-6:30, Wed. 10:00-3:30
WHERE BIO 2005 Annual International Convention, Philadelphia
Booth #564 (in California Section)
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
Hope is a waking dream.